SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Citizens upgrades Quince Therapeutics to Market Outperform, $77 target

Citizens upgraded Quince Therapeutics to Market Outperform and set a $77.00 price target, implying 148.4% upside from the Sep 21 close of $31.00.

QNCX

Citizens upgraded Quince Therapeutics to Market Outperform and set a price target of $77.00. The target implies upside of 148.4% from the Sep 21 close of $31. The analyst note cited recent encouraging Phase 2a clinical data from Quince Therapeutics.

Related stories